• 1. A review: the botany, ethnopharmacology, phytochemistry, pharmacology of Cinnamomi cortex
  Songtao Liu,Liu Yang,Senwang Zheng,Ajiao Hou,Wenjing Man,Jiaxu Zhang,Song Wang,Xuejiao Wang,Huan Yu,Hai Jiang RSC Adv. 2021 11 27461
• 2. 1-Ethoxyvinyl carboxylates as 1,4-dipolar reagents. Conversion of aldehydes into β-hydroxy-esters
  Harry H. Wasserman,Stephen H. Wentland J. Chem. Soc. D 1969 1216b

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Cinnamic acids and derivatives Coumaric acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Cinnamic acids and derivatives Hydroxycinnamic acids and derivatives Coumaric acids and derivatives

Recent Advances in the Study of Ethyl (E)-3-(2-Methoxyphenyl)prop-2-enoate (CAS: 24393-54-2) in Chemical Biology and Pharmaceutical Research

Ethyl (E)-3-(2-Methoxyphenyl)prop-2-enoate (CAS: 24393-54-2) is a cinnamic acid derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This compound, characterized by its α,β-unsaturated ester moiety and methoxy-substituted aromatic ring, has been the subject of numerous studies exploring its biological activities, synthetic pathways, and pharmacological properties. The latest research highlights its role as a versatile scaffold for the design of novel therapeutic agents, particularly in the areas of anti-inflammatory, anticancer, and antimicrobial drug discovery.

Recent studies have focused on the synthesis and optimization of Ethyl (E)-3-(2-Methoxyphenyl)prop-2-enoate derivatives to enhance their bioactivity and pharmacokinetic profiles. A 2023 publication in the Journal of Medicinal Chemistry demonstrated that structural modifications at the ester group and the aromatic ring significantly influence the compound's binding affinity to target proteins, such as cyclooxygenase-2 (COX-2) and histone deacetylases (HDACs). These findings underscore the compound's potential as a lead structure for developing selective enzyme inhibitors with reduced off-target effects.

In addition to its pharmacological applications, Ethyl (E)-3-(2-Methoxyphenyl)prop-2-enoate has been investigated for its role in chemical biology as a fluorescent probe and a photoaffinity labeling agent. A study published in ACS Chemical Biology (2024) utilized this compound to develop a novel probe for real-time imaging of intracellular reactive oxygen species (ROS) in cancer cells. The probe's high selectivity and sensitivity were attributed to the unique electronic properties conferred by the methoxyphenyl and α,β-unsaturated ester functionalities, enabling precise detection of ROS dynamics in live cells.

The compound's mechanism of action has also been elucidated through advanced computational and experimental techniques. Molecular docking and molecular dynamics simulations, as reported in a 2024 Nature Communications article, revealed that Ethyl (E)-3-(2-Methoxyphenyl)prop-2-enoate interacts with key residues in the active sites of target enzymes, stabilizing specific conformations that inhibit their catalytic activity. These insights have paved the way for rational drug design approaches aimed at optimizing the compound's therapeutic efficacy.

Despite these advancements, challenges remain in the clinical translation of Ethyl (E)-3-(2-Methoxyphenyl)prop-2-enoate-based therapeutics. Issues such as metabolic stability, bioavailability, and potential toxicity need to be addressed through further preclinical studies. Ongoing research is exploring prodrug strategies and nanoparticle-based delivery systems to overcome these limitations, as highlighted in a recent review in Advanced Drug Delivery Reviews (2024).

In conclusion, Ethyl (E)-3-(2-Methoxyphenyl)prop-2-enoate (CAS: 24393-54-2) represents a promising candidate for drug development and chemical biology applications. Its versatile chemical structure and diverse biological activities make it a valuable tool for researchers aiming to discover new therapeutic agents and elucidate complex biological mechanisms. Future studies should focus on optimizing its pharmacological properties and advancing it through the drug development pipeline to realize its full potential in clinical settings.

• 50636-22-1(2-Propenoic acid,3-(2-ethoxyphenyl)-, ethyl ester)
• 33877-05-3(2-Propenoic acid,3-(2-methoxyphenyl)-, ethyl ester)
• 107274-42-0(2-Propenoic acid, 3-(2-methoxy-5-methylphenyl)-, ethyl ester)
• 81069-40-1(2-Propenoic acid, 3-[2-(acetyloxy)phenyl]-, ethyl ester, (E)-)
• 67827-53-6(Ethyl 2,4,6-Trimethoxycinnamate)
• 86867-64-3(Ethyl 3-(2-phenoxyphenyl)prop-2-enoate)
• 89229-13-0(2-Propenoic acid, 3-(2,7-dimethoxy-1-naphthalenyl)-, ethyl ester)
• 84385-05-7(2-Propenoic acid, 3-(2-methoxyphenyl)-, methyl ester, (Z)-)
• 139386-27-9(2-Propenoic acid, 3-(2-hydroxy-4-methoxyphenyl)-, ethyl ester, (E)-)
• 477779-96-7